Results 251 to 260 of about 237,895 (332)
Correction to: EGFR signaling augments TLR4 cell surface expression and function in macrophages via regulation of Rab5a activation [PDF]
openalex +1 more source
ABSTRACT IgA nephropathy (IgAN), the most common form of glomerulonephritis, is a major and growing public health issue. It results from intestinal barrier dysfunction that leads to mesangial deposition of pathogenic galactose‐deficient IgA1 (Gd‐IgA1) and renal inflammation.
Meng‐Si Li, Kai Liu
wiley +1 more source
Bicuculline from <i>Forsythia suspensa</i> attenuates liver fibrosis via TLR4/MD2 inhibition and suppression of MyD88/NF-κB signaling. [PDF]
Zhang X +6 more
europepmc +1 more source
ABSTRACT This study aimed to assess whether admission plasma lipopolysaccharide‐binding protein (LBP), procalcitonin (PCT), and lactate could improve detection of nosocomial infection in cirrhotic patients presenting with upper gastrointestinal bleeding (UGIB).
Li Chen, Shan‐Shan Dun, Fang Xiao
wiley +1 more source
Current Perspectives on the NF-κB Signaling Axis as a Potential Pharmacological Target in Cardiorenal Syndrome. [PDF]
Liu Q +5 more
europepmc +1 more source
ABSTRACT Although sphingolipids are key players in lipotoxicity and metabolic diseases, their response to bariatric surgery and their relation to metabolic improvement remain unclear. This pilot study investigated plasma sphingolipid remodeling after Roux‐en‐Y gastric bypass (RYGB) and its associations with clinical and biochemical markers of ...
Gabriela de Oliveira Lemos +3 more
wiley +1 more source
Designing a Multi-Epitope Vaccine Against NOTCH1 and NOTCH4: A Computational Approach for Triple-Negative Breast Cancer. [PDF]
Teimoori P, Khatir K, Heidari M.
europepmc +1 more source
Design, synthesis and biological characterization of new small-molecule TLR4 modulators
Roberto Cighetti
openalex +1 more source
Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy
ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley +1 more source

